NASDAQ:ABEO Abeona Therapeutics (ABEO) Stock Price, News & Analysis $7.23 +0.12 (+1.69%) Closing price 04:00 PM EasternExtended Trading$7.21 -0.02 (-0.28%) As of 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Abeona Therapeutics Stock (NASDAQ:ABEO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Abeona Therapeutics alerts:Sign Up Key Stats Today's Range$7.12▼$7.3950-Day Range$5.57▼$7.2352-Week Range$3.93▼$7.54Volume850,820 shsAverage Volume1.02 million shsMarket Capitalization$370.75 millionP/E Ratio10.33Dividend YieldN/APrice Target$19.50Consensus RatingBuy Company Overview Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas. Read More Abeona Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks89th Percentile Overall ScoreABEO MarketRank™: Abeona Therapeutics scored higher than 89% of companies evaluated by MarketBeat, and ranked 128th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAbeona Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAbeona Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Abeona Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Abeona Therapeutics are expected to decrease in the coming year, from ($1.16) to ($1.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Abeona Therapeutics is 10.33, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.39.Price to Earnings Ratio vs. SectorThe P/E ratio of Abeona Therapeutics is 10.33, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 31.15.Price to Book Value per Share RatioAbeona Therapeutics has a P/B Ratio of 2.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.51% of the float of Abeona Therapeutics has been sold short.Short Interest Ratio / Days to CoverAbeona Therapeutics has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Abeona Therapeutics has recently decreased by 0.71%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbeona Therapeutics does not currently pay a dividend.Dividend GrowthAbeona Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.03 Percentage of Shares Shorted18.51% of the float of Abeona Therapeutics has been sold short.Short Interest Ratio / Days to CoverAbeona Therapeutics has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Abeona Therapeutics has recently decreased by 0.71%, indicating that investor sentiment is improving. News and Social Media2.5 / 5News Sentiment0.57 News SentimentAbeona Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Abeona Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for ABEO on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows7 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Abeona Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,430,587.00 in company stock.Percentage Held by InsidersOnly 6.90% of the stock of Abeona Therapeutics is held by insiders.Percentage Held by Institutions80.56% of the stock of Abeona Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Abeona Therapeutics' insider trading history. Receive ABEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ABEO Stock News HeadlinesHC Wainwright Has Negative Estimate for ABEO Q3 EarningsAugust 22 at 2:15 AM | americanbankingnews.comZacks Small Cap Issues Optimistic Estimate for ABEO EarningsAugust 22 at 2:29 AM | americanbankingnews.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.August 22 at 2:00 AM | Porter & Company (Ad)Abeona Therapeutics Inc. (NASDAQ:ABEO) Q2 2025 Earnings Call TranscriptAugust 20 at 5:46 PM | msn.comQ1 EPS Estimate for Abeona Therapeutics Reduced by AnalystAugust 20 at 2:54 AM | americanbankingnews.comAbeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call TranscriptAugust 19 at 4:19 PM | seekingalpha.comABEO: First Patient Treatment with Zevaskyn Expected in 3Q25…August 18, 2025 | finance.yahoo.comAbeona Therapeutics (NASDAQ:ABEO) Stock Price Expected to Rise, Oppenheimer Analyst SaysAugust 18, 2025 | americanbankingnews.comSee More Headlines ABEO Stock Analysis - Frequently Asked Questions How have ABEO shares performed this year? Abeona Therapeutics' stock was trading at $5.57 at the start of the year. Since then, ABEO shares have increased by 29.8% and is now trading at $7.23. How were Abeona Therapeutics' earnings last quarter? Abeona Therapeutics Inc. (NASDAQ:ABEO) posted its earnings results on Thursday, August, 14th. The biopharmaceutical company reported $1.71 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $2.10. The biopharmaceutical company had revenue of $0.40 million for the quarter, compared to analyst estimates of $21.71 million. Read the conference call transcript. When did Abeona Therapeutics' stock split? Abeona Therapeutics shares reverse split on Tuesday, July 5th 2022.The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are Abeona Therapeutics' major shareholders? Abeona Therapeutics' top institutional shareholders include Adage Capital Partners GP L.L.C. (6.01%), Boone Capital Management LLC (2.45%), Geode Capital Management LLC (2.16%) and JPMorgan Chase & Co. (1.62%). Insiders that own company stock include Vishwas Seshadri, Joseph Walter Vazzano, Brendan M O'malley, Faith L Charles, Christine Berni Silverstein, Michael Amoroso, Leila Alland and Mark Alvino. View institutional ownership trends. How do I buy shares of Abeona Therapeutics? Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Abeona Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Abeona Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), CymaBay Therapeutics (CBAY) and GE Aerospace (GE). Company Calendar Last Earnings8/14/2025Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABEO Previous SymbolOTCMKTS:ACCP CIK318306 Webwww.abeonatherapeutics.com Phone214-665-9495Fax214-905-5101Employees90Year FoundedN/APrice Target and Rating Average Price Target for Abeona Therapeutics$19.50 High Price Target$20.00 Low Price Target$18.00 Potential Upside/Downside+169.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$0.70 Trailing P/E Ratio10.33 Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.73 million Net MarginsN/A Pretax Margin18,188.50% Return on Equity89.05% Return on Assets45.64% Debt Debt-to-Equity Ratio0.09 Current Ratio6.73 Quick Ratio4.90 Sales & Book Value Annual Sales$400 thousand Price / Sales926.87 Cash FlowN/A Price / Cash FlowN/A Book Value$3.19 per share Price / Book2.27Miscellaneous Outstanding Shares51,279,000Free Float47,741,000Market Cap$370.75 million OptionableOptionable Beta1.55 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ABEO) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Abeona Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.